Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Sanne H. Tonino"'
Autor:
Johanna A. A. Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H. Tonino, Joost S. P. Vermaat, Martine E. D. Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J. Plattel, Mirian Brink, Marcel Nijland
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unkno
Externí odkaz:
https://doaj.org/article/c575b728501f4006bbbe73caea67c694
Autor:
Manette A. W. Dinnessen, Otto Visser, Sanne H. Tonino, Eduardus F. M. Posthuma, Nicole M. A. Blijlevens, Marie José Kersten, Pieternella J. Lugtenburg, Avinash G. Dinmohamed
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/096b45dd824344278e437f224fb8a433
Autor:
Manette A. W. Dinnessen, Otto Visser, Sanne H. Tonino, Eduardus F. M. Posthuma, Nicole M. A. Blijlevens, Marie José Kersten, Pieternella J. Lugtenburg, Avinash G. Dinmohamed
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/99defe98cd344358a21d34feb9b0ca4e
Autor:
Manette A.W. Dinnessen, Otto Visser, Sanne H. Tonino, Marjolein W.M. van derPoel, Nicole M.A. Blijlevens, Marie José Kersten, Pieternella J. Lugtenburg, Avinash G. Dinmohamed
Publikováno v:
eJHaem, Vol 1, Iss 2, Pp 489-497 (2020)
Abstract We assessed the impact of a prior malignancy diagnosis (PMD) – as a potential proxy for genetic cancer susceptibility – on the development of a second primary malignancy (SPM) and mortality in follicular lymphoma (FL) patients. From the
Externí odkaz:
https://doaj.org/article/dfa9b778bf134e4ab8e827d8c61d9710
Autor:
Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B.M. Remmerswaal, Frederike J. Bemelman, Carsten U. Niemann, Sabina Kersting, Mark-David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2642-2652 (2019)
Abstract: Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although immunosuppression is considered to originate within the lymph node (LN) microenvironment, alterat
Externí odkaz:
https://doaj.org/article/9b70facd4d2e4144a9ac742f72e1a6b0
Autor:
Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Wouter J. Plattel, Franck Morschhauser, Pieternella J. Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N. Burggraaff, Marcel Nijland, Sanne H. Tonino, Anne I.J. Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong, Anton Hagenbeek
Publikováno v:
Haematologica, Vol 106, Iss 4 (2020)
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
Externí odkaz:
https://doaj.org/article/4d92849800704d5a8879878670f84aeb
Autor:
Tom Hofland, Iris de Weerdt, Sanne Endstra, Aldo Jongejan, Laura Platenkamp, Ester B.M. Remmerswaal, Perry D. Moerland, Ineke J.M. ten Berge, Mark-David Levin, Arnon P. Kater, Sanne H. Tonino
Publikováno v:
HemaSphere, Vol 4, Iss 2, p e337 (2020)
Abstract. Acquired T cell dysfunction is a hallmark of chronic lymphocytic leukemia (CLL), and is linked to an increased risk of infections, but also reduced immune surveillance and disappointing responses to autologous T cell-based immunotherapy. Th
Externí odkaz:
https://doaj.org/article/ffac109445dc47468b9b6719d21181a3
Autor:
Tom Hofland, Sanne Endstra, Calum K.P. Gomes, Renate de Boer, Iris de Weerdt, Vladimir Bobkov, Jurgen A. Riedl, Raimond Heukers, Martine J. Smit, Eric Eldering, Mark-David Levin, Arnon P. Kater, Sanne H. Tonino
Publikováno v:
HemaSphere, Vol 3, Iss 6, p e308 (2019)
Abstract. Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction, which may underlie the hampered efficacy of cellular immunotherapy. Most data on dampened immune responses in CLL come from studies investigating CLL and
Externí odkaz:
https://doaj.org/article/9347461bef564194919c7d0ee31cc143
Autor:
Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink, Anne-Marie F van der Kevie-Kersemaekers, Ludo M Evers, Fransien de Boer, Harry R Koene, John Schreurs, Marjolein van der Klift, Gerjo A Velders, Ellen van der Spek, Hanneke M van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F M Posthuma, Hein P J Visser, Ilse Houtenbos, Cecile A M Idink, Djamila E Issa, Ellen C Dompeling, Henk C T van Zaanen, Hendrik Veelken, Henriette Levenga, Lidwine W Tick, Wim E Terpstra, Sanne H Tonino, Michelle Boyer, Mehrdad Mobasher, Mark-David Levin, Arnon P Kater
Publikováno v:
The Lancet Haematology, 9(3), e190-e199. Lancet Publishing Group
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
Background Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0986e715312f80218fa9f8521d8b97ab
https://doi.org/10.1016/s2352-3026(22)00034-5
https://doi.org/10.1016/s2352-3026(22)00034-5
Autor:
Anton Hagenbeek, Julia Driessen, Roberto D Liu, Marcel Nijland, Pauline Brice, Wouter J. Plattel, Roelf Valkema, Thomas Gastinne, Harm van Tinteren, Marie José Kersten, Martin Hutchings, Pieternella J. Lugtenburg, Sanne H. Tonino, Daphne de Jong, Arjan Diepstra, Josée M. Zijlstra, Franck Morschhauser, Marta Lopez-Yurda, Coreline N. Burggraaff, Anne I.J. Arens
Publikováno v:
Haematologica, 106(4), 1129-1137. Ferrata Storti Foundation
Haematologica, 106, 1129-1129
Haematologica
Kersten, M J, Driessen, J, Zijlstra, J M, Plattel, W J, Morschhauser, F, Lugtenburg, P J, Brice, P, Hutchings, M, Gastinne, T, Liu, R, Burggraaff, C N, Nijland, M, Tonino, S H, Arens, A I J, Valkema, R, van Tinteren, H, Lopez-Yurda, M, Diepstra, A, De Jong, D & Hagenbeek, A 2021, ' Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma : the phase II HOVON/LLPC Transplant BRaVE study ', Haematologica, vol. 106, no. 4, pp. 1129-1137 . https://doi.org/10.3324/haematol.2019.243238
Haematologica, 106(4), 1129-1136. FERRATA STORTI FOUNDATION
Haematologica, 106, 4, pp. 1129-1129
Haematologica, 106, 1129-1129
Haematologica
Kersten, M J, Driessen, J, Zijlstra, J M, Plattel, W J, Morschhauser, F, Lugtenburg, P J, Brice, P, Hutchings, M, Gastinne, T, Liu, R, Burggraaff, C N, Nijland, M, Tonino, S H, Arens, A I J, Valkema, R, van Tinteren, H, Lopez-Yurda, M, Diepstra, A, De Jong, D & Hagenbeek, A 2021, ' Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma : the phase II HOVON/LLPC Transplant BRaVE study ', Haematologica, vol. 106, no. 4, pp. 1129-1137 . https://doi.org/10.3324/haematol.2019.243238
Haematologica, 106(4), 1129-1136. FERRATA STORTI FOUNDATION
Haematologica, 106, 4, pp. 1129-1129
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplant (auto-PBSCT) predicts progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2319065b3dca13fbddf9056a28a1f65f
https://research.rug.nl/en/publications/d7844e9e-fb58-46a6-90c3-61fa5f40a19c
https://research.rug.nl/en/publications/d7844e9e-fb58-46a6-90c3-61fa5f40a19c